Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735, as the biotech positions itself to ...

The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could ...

The agreement provides Viking with a sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity. Under the ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

The firm’s analyst highlighted positive data from a competitor’s clinical trial, which reinforces the potential of Viking’s own treatment, VK2735, for obesity. While the stock has experienced a ...

So if you plan to call it quits at work within a decade, or you’ve just retired, you may want to take steps to minimize what’s called sequence risk, which is the risk that the market falls ...

SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ: VKTX), currently valued at $3.14 billion, has entered into a strategic manufacturing agreement with CordenPharma to ensure a steady supply of its VK2735 ...

Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma ...

The firm’s analyst highlighted positive data from a competitor’s clinical trial, which reinforces the potential of Viking’s own treatment, VK2735, for obesity. While the stock has ...

Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector ...